Biovest’s BiovaxID® Lymphoma Vaccine Featured in FierceBiotech Cancer Immunotherapy Special Report

Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that a special report published by FierceBiotech highlights Biovest’s BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

The article, titled “Cancer Immunotherapy Production: Overcoming Obstacles to Profitability” by Suzanne Elvidge, reports that, “Perhaps one route to successful and profitable personalized cancer vaccines is taking a much simpler approach. Biovest’s BiovaxID platform starts with a lymphoma tumor sample. The cancerous B-cells in this sample have receptors on their surface that are crucial for the tumor cell’s survival. Rather than using the whole cell, Biovest creates copies of the cell receptors (idiotype) on the patient’s tumor cells, which are then given as a vaccine with GM-CSF and KLH, a foreign protein that kicks off an immune response, resulting in destruction of the cells.”

The article also notes, “One of the advantages of Biovest’s approach is that all the patient-specific doses can be made at the same time and stored, immediately cutting costs.”

The complete article can be accessed in the Media Center at Biovest’s corporate website at: http://www.biovest.com/investor-relations/media-center

Biovest’s President & CEO, Samuel S. Duffey, added, “In contrast to the often complex and expensive methods used to manufacture cell-based autologous cancer vaccines, BiovaxID manufacture is relatively straight-forward: we rely upon a largely automated process that yields small-batches of a patient-specific idiotype (antibody) protein. To manufacture BiovaxID, we rely on well-controlled processes adapted from, and similar to, classic manufacturing of antibody products worldwide. Accordingly, our commercialization strategy requires only one centralized manufacturing facility to meet demand as opposed to multiple facilities. In addition, BiovaxID’s shipping and handling resemble in most aspects the shipping and handling of currently marketed antibody drug products. Perhaps most importantly for our patients, however, BiovaxID therapy requires only a series of subcutaneous injections instead of highly cumbersome, hours-long intravenous infusion procedures.”

Interested parties can subscribe to FierceBiotech’s free daily newsletter by visiting: http://www.fiercebiotech.com/

About Biovest International, Inc.

Biovest International, Inc. develops active immunotherapies (cancer vaccines) which treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma, a cancer of the immune system. The Company’s lead personalized cancer vaccine product candidate, BiovaxID®, has been evaluated in three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) demonstrating that BiovaxID increases the duration of cancer remission following chemotherapy and induces immune responses which correlate highly with long-term survival. Biovest is currently in the process of seeking US and international marketing approvals for BiovaxID.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”).

For further information, please visit: http://www.biovest.com

Forward-Looking Statements:

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID® and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. In particular (and without limitation), statements regarding the timing of anticipated filing of a Marketing Authorization Application for BiovaxID with the EMA or a New Drug Submission for BiovaxID with Health Canada, pre-filing meetings with the FDA or other jurisdictions and/or commercial plans reflect current expectations but are subject to inherent risks of delay in compilation and finalization of all components of the licensing application. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.